🇺🇸 Cephalozin in United States

FDA authorised Cephalozin on 10 September 1985 · 10 US adverse-event reports

Marketing authorisations

FDA — authorised 10 September 1985

  • Application: ANDA062557
  • Marketing authorisation holder: LILLY
  • Local brand name: KEFZOL
  • Indication: INJECTABLE — INJECTION
  • Status: approved

Read official source →

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Agitation — 1 report (10%)
  2. Antipsychotic Drug Level Increased — 1 report (10%)
  3. Bacterial Infection — 1 report (10%)
  4. Cardiopulmonary Failure — 1 report (10%)
  5. Cellulitis — 1 report (10%)
  6. Cerebral Atrophy — 1 report (10%)
  7. Death — 1 report (10%)
  8. Depressed Level Of Consciousness — 1 report (10%)
  9. Drug Ineffective — 1 report (10%)
  10. Endocarditis — 1 report (10%)

Source database →

Cephalozin in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in United States

Frequently asked questions

Is Cephalozin approved in United States?

Yes. FDA authorised it on 10 September 1985; FDA has authorised it.

Who is the marketing authorisation holder for Cephalozin in United States?

LILLY holds the US marketing authorisation.